Recombinant Human Siglec-2 / CD22 Protein, Llama IgG2b Fc Tag, low endotoxin, 100 µg

Background
B-cell receptor CD22 is also known as Sialic acid-binding Ig-like lectin 2 (Siglec-2), B-lymphocyte cell adhesion molecule (BL-CAM), T-cell surface antigen Leu-14, which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. CD22 mediates B-cell B-cell interactions, and may be involved in the localization of B-cells in lymphoid tissues. Siglec-2 / CD22 binds sialylated glycoproteins, one of which is CD45. Siglec2 / CD22 plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.

Source
Recombinant Human Siglec-2, Llama IgG2b Fc Tag, low endotoxin (SI2-H525a) is expressed from human 293 cells (HEK293). It contains AA Asp 20 - Arg 687 (Accession # P20273-1).
Predicted N-terminus: Asp 20

Molecular Characterization
This protein carries a llama IgG2b Fc tag at the C-terminus.
The protein has a calculated MW of 103.0 kDa. The protein migrates as 120-140 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 0.01 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20^°C to -70^°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells"
Fergusson, Adeel, Kekre et al
Front Immunol (2023) 14, 1178403
(2) "Siglec cis-ligands and their roles in the immune system"
Tsubata
Glycobiology (2023)
(3) "Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL"
Qiu, Wan, Xu et al
Blood Cancer J (2023) 13 (1), 66
Showing 1-3 of 989 papers.